Advocacy intelligence hub — real-time data for patient organizations
Tisento Therapeutics — PHASE2
Thiogenesis Therapeutics, Inc. — PHASE2
Rigshospitalet, Denmark — PHASE3
Tisento Therapeutics — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Michio Hirano, MD, M.D
Columbia University
📍 NEW YORK, NY
FERNANDO SCAGLIA, M.D
Baylor College of Medicine
Ingrid Tein, MD
The Hospital for Sick Children
Arash L Afshari, MD, PhD
Rigshospitalet, Denmark
Patrice P Rioux, MD, PhD
Thiogenesis Therapeutics, Inc.
Elizabeth M McCormick, MS
Children's Hospital of Philadelphia